Implanet S.A.
IMPZY
Other OTC0.08
USD
- -
- -
Implanet S.A.
IMPZY
(Other OTC)
Recent
price
0.08
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Implanet S.A. specializes in the design, production, and sale of orthopedic surgical implants and medical instruments, primarily focused on spine and knee surgery. Its core product portfolio includes spinal fixation systems such as the Jazz® Spinal System™ hybrid fixation range, implantable screws, anchors, sutures, acetabular cups, and knee prostheses marketed under the Madison brand. The company also offers ultrasonic osteotomy surgical systems and various associated medical devices. Implanet operates internationally with significant geographic markets including France, the United States, Europe, the Middle East, Africa, and China. Founded in 2006 and headquartered in Martillac, France, Implanet targets healthcare institutions, surgeons, and specialized surgical centers. Recent major developments include the 2024 launch of the Jazz® Spinal System™ hybrid fixation system, a unique new range of spinal implants cleared by the FDA for the U.S. market. In 2024, Implanet successfully completed a €5.5 million capital increase and secured approximately €2 million in financing from Shanghai Pudong Development Bank, underpinning expansion efforts. The company also strengthened its U.S. presence by appointing a new general manager and signing an exclusive partnership for the distribution of the Olea ultrasonic surgical scalpel for endoscopic spine surgery. Furthermore, Implanet entered a strategic commercial and technological partnership with Sanyou Medical to jointly develop and distribute advanced hybrid posterior fixation systems in Europe and expand the Jazz® platform into China, the world’s largest spine market by volume. The company continues to invest in regulatory compliance including European Medical Device Regulation (MDR) registration and aims to enhance market reach through expanding its scientific team and commercial capabilities. Implanet’s business is concentrated in the surgical orthopedic implant segment, with spinal products accounting for the majority of revenue, complemented by knee surgery implants and medical equipment distribution. The company maintains operations through subsidiaries and partners across multiple regions including Europe, the Americas, and Asia. Its product development emphasizes innovation in spinal surgery with a focus on hybrid fixation technologies and incorporation of advanced medical equipment solutions such as ultrasonic surgical instruments. Implanet S.A. employs approximately 46 people and is led by CEO Ludovic Lastennet. The company maintains its headquarters in Martillac, France, and is publicly traded under the ticker IMPZY. Its recent strategic moves and product launches reinforce its positioning as a key player in the global orthopedic surgery market with a particular leadership role in spinal implant technology advancement. This description draws on Implanet’s latest 2024-2025 financial and strategic updates, product developments, and geographic expansion initiatives as publicly reported.